For the year ending 2025-12-31, INO made $65,343 in revenue. -$84,945,901 in net income. Net profit margin of -130000.00%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Revenue from collaborative arrangement | 65,343 | |||
| Research and development | 54,206,874 | |||
| General and administrative | 32,680,573 | |||
| Total operating expenses | 86,887,447 | |||
| Loss from operations | -86,822,104 | |||
| Interest income | 2,420,160 | |||
| Interest expense | 0 | |||
| Change in fair value of common stock warrant liabilities | -493,231 | |||
| Gain (loss) on investment in affiliated entity | 489,844 | |||
| Net unrealized gain on available-for-sale equity securities | 1,114,781 | |||
| Other expense, net | -2,641,813 | |||
| Net loss | -84,945,901 | |||
| Basic EPS | -1.81 | |||
| Diluted EPS | -1.81 | |||
| Basic Average Shares | 46,886,413 | |||
| Diluted Average Shares | 46,886,413 | |||
INOVIO PHARMACEUTICALS, INC. (INO)
INOVIO PHARMACEUTICALS, INC. (INO)